期刊
GUT MICROBES
卷 12, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2020.1813533
关键词
Clostridioides difficile; endolysin; bacteriophage; antimicrobials; clostridioides difficileinfections; antibiotics; novel therapy
资金
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [754535]
Clostridioides difficileis the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment ofC. difficileinfections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages ofC. difficileand their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues ofC. difficileendolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据